Nolan A Wages, Ph.D.

Public Health Sciences

Nolan A Wages, Ph.D.

Assistant Professor
Translational Research & Applied Statistics
Ph.D., Statistics, University of Virginia, 2010

P.O. Box 800717
Tel: 1-434-924-8222
Fax: 1-434-243-5787
West Complex OMS Room 3890

Research Interests:

  • Design and analysis of early-phase clinical trials in oncology.


Teaching Responsibilities:

  • Introduction to Statistics session, Foundations of Medicine, Fall 2014
  • Biostatistics Short Course to Rad/Onc Residents and Heme/Onc Fellows, Spring 2014
  • PHS 7000 - Biostatistics I, J-Term 2014


Other Information:


  1. Wages NA, Conaway MR, Slingluff CL, Williams ME, Portell CA, Hwu P, Petroni GR. (2015). Recent developments in the implementation of novel designs for early-phase combination studies. Annals of Oncology; to appear.
  2. Romano AM, Wages NA, Smolkin M, La Fortune K, Atkins K, Dillon PM. (2015). Low-grade tubular carcinoma of the breast: institutional and SEER database analysis supporting a unique classification. Breast Disease; to appear.
  3. Wages NA, Tait C. (2015). Seamless phase I/II adaptive design for oncology trials of molecularly targeted agents. J Biopharm Stat; [epub ahead of print].
  4. Wages NA, Slingluff CL, Petroni GR. (2015). A phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma. Contemporary Clinical Trials; 41: 172-79.
  5. Wages NA. (2015). Comments on 'Competing designs for drug combination phase I dose-finding clinical trials' by M-K. Riviere, F. Dubois, S. Zohar. Stat Med; 34: 18-22.
  6. Wages NA, Conaway MR, O'Quigley J. (2014). Comments on 'A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials' by Akihiro Hirakawa, Chikuma Hamada, and Shigeyuki Matsui. Stat Med; 33: 2156-2158.
  7. Wages NA, Conaway MR. (2014). Phase I/II adaptive design for drug combination oncology trials. Stat Med; 33: 1990-2003.
  8. Showalter TN, Wages NA, Ohri N. (2014). Strategic evaluation of interventions to prevent consequential late proctitis after prostate radiation therapy: New clinical trial designs should be considered. Cancer Biol Ther; 15: 361-364.
  9. Wages NA, O'Quigley J, Conaway MR. (2014). Phase I design for completely or partially ordered treatment schedules. Stat Med; 33: 569-579.
  10. Wages NA, Conaway MR, O'Quigley J. (2013). Performance of two-stage continual reassessment method relative to an optimal benchmark. Clin Trials; 10: 862-875.
  11. Wages NA, Varhegyi N. (2013). pocrm: An R package for phase I trials of combinations of agents. Comput Methods Programs Biomed; 112: 211-218.
  12. Wages NA, Conaway MR. (2013). Specifications of a continual reassessment method design for phase I trials of combined drugs. Pharm Stat; 12: 217-224.
  13. Wages NA, Conaway MR, O’Quigley J. (2013). Using the time-to-event continual reassessment method in the presence of partial orders. Stat Med; 32: 131–141.
  14. Wages NA, Liu L, O’Quigley J, Johnson B. (2012). Obtaining the optimal dose in alcohol dependence studiesFront Psychiatry; 3:100.
  15. Wages NA, Conaway MR, O’Quigley J. (2011). Continual reassessment method for partial ordering. Biometrics; 67: 1555–1563.
  16. Wages NA, Conaway MR, O’Quigley J. (2011). Dose-finding design for multi-drug combinations. Clin Trials; 8: 380–389.
  17. O'Quigley J, Wages NA. (2008). Dose escalation guided by graded toxicities. Wiley Encyclopedia of Clin Trials; 1-6